Locations:
SearchAdvertisement
Yet 21.4% of tested individuals had Lp(a) elevation
Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose
Tech-assisted self-selection concurred with clinician-assessed eligibility in >90% of cases
Newly identified pathway may explain the so-called niacin paradox
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
It's time to increase testing for this major cardiovascular risk factor in advance of new therapies
Undetectable levels achieved for nearly nine months in phase 1 trial
Randomized controlled study undercuts unsubstantiated ‘heart health’ claims
Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor
Preclinical models focus interest on the protein hepsin
New phase 2 data boost hopes for phase 3 Lp(a) HORIZON trial
Advertisement
Advertisement